Alnylam Pharmaceuticals Inc ALNY:NASDAQ

Last Price$75.37NASDAQ Previous Close - Last Trade as of 3:59PM ET 7/19/19

Today's Change-0.52(0.69%)
Bid (Size)$74.70 (1)
Ask (Size)$79.00 (1)
Day Low / High$74.75 - 75.95
Volume1.3 M

View Biotechnology IndustryPeer Comparison as of 07/19/2019


Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $75.37
Change: -0.52 (0.69%)
Volume: 1.3 M
3:59PM ET 7/19/2019

Bio-Techne Corp ( NASDAQ )

Price: $209.47
Change: -4.95 (2.31%)
Volume: 186.0 K
3:59PM ET 7/19/2019

Neurocrine Biosciences Inc ( NASDAQ )

Price: $85.71
Change: -2.80 (3.16%)
Volume: 573.0 K
4:00PM ET 7/19/2019

bluebird bio Inc ( NASDAQ )

Price: $138.21
Change: +0.09 (0.07%)
Volume: 466.0 K
4:00PM ET 7/19/2019

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $68.76
Change: 0.00 (0.00%)
Volume: 1.3 M
4:00PM ET 7/19/2019

Read more news Recent News

Alnylam Teams Up With 23andMe to Support Patients With TTR-Related Hereditary Amyloidosis
10:42AM ET 7/16/2019 MT Newswires

Alnylam Pharmaceuticals (ALNY) said Tuesday it has partnered with consumer genetics company 23andMe to offer free Health + Ancestry kits to first-degree...

Alnylam Pharmaceuticals Names New CFO After Manmeet Soni Steps Down
9:26AM ET 7/11/2019 MT Newswires

Alnylam Pharmaceuticals (ALNY) said Thursday that it has appointed Jeff Poulton as Chief Financial Officer and Executive Vice President, effective Aug. 13....

Arbutus Sells Part of its Onpattro Royalty Interest to Canada's OMERS
4:19PM ET 7/02/2019 MT Newswires

Arbutus Biopharma (ABUS) said after markets closed on Tuesday that it has sold part of its royalty interest on future global sales of Onpattro to OMERS,...

Alnylam Pharma Files Marketing Authorization Application in Europe for Treatment of Acute Hepatic Porphyria
7:38AM ET 7/01/2019 MT Newswires

Alnylam Pharmaceuticals (ALNY) said early Monday it submitted a marketing authorization application to the European Medicines Agency (EMA) for givosiran,...

View all Commentary and Analysis

Horizon's NDA for Procysbi New Dosage Form Accepted by FDA
8:41AM ET 7/19/2019 Zacks

The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate)...

Dicerna: An RNA Therapy-Based 21st Century Likely Winner
1:14AM ET 7/12/2019 Seeking Alpha

BIIB Is For Buy-O-Gen
10:30AM ET 6/12/2019 Seeking Alpha

Alnylam Pharmaceuticals (ALNY) Investor Presentation - Slideshow
11:37AM ET 6/10/2019 Seeking Alpha

Company Profile

Business DescriptionAlnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. View company web site for more details
Address300 Third Street
Cambridge, Massachusetts 02142
Number of Employees1,065
Recent SEC Filing07/11/20198-K
Chief Executive Officer & DirectorJohn M. Maraganore
PresidentBarry E. Greene
Chief Operating Officer & Executive Vice PresidentYvonne L. Greenstreet
Senior VP, Chief Financial & Accounting OfficerManmeet Singh Soni

Company Highlights

Price Open$75.95
Previous Close$75.89
52 Week Range$60.27 - 124.22
Market Capitalization$8.0 B
Shares Outstanding106.5 M
SectorHealth Technology
Next Earnings Announcement08/01/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$8.02
Beta vs. S&P 500N/A
Revenue$74.9 M
Net Profit Margin-929.51%
Return on Equity-53.95%

Analyst Ratings as of 07/12/2019

Consensus RecommendationConsensus Icon
Powered by Factset